Zhitong Finance App News, Okanvision Bio-B (01477.HK) announced that the Group's self-developed product OT 802 (pilocarpine hydrochloride eye drops) phase III clinical trial authorization for presbyopia indications was recently approved by the Drug Evaluation Center of the People's Republic of China (China) State Drug Administration. A randomized, double-blind, placebo-controlled, parallel group, multi-center clinical trial can be carried out. The presbyopia treatment market has huge commercial potential, particularly in China, where no pharmaceuticals have been approved for commercial use until now. The OT-802 phase III clinical trial authorization was obtained this time, which reflects the Group's research and development capabilities, and highlights that the current presbyopia treatment market is unsatisfied and has considerable potential.

Zhitong Finance App News, Okanvision Bio-B (01477.HK) announced that the Group's self-developed product OT 802 (pilocarpine hydrochloride eye drops) phase III clinical trial authorization for presbyopia indications was recently approved by the Drug Evaluation Center of the People's Republic of China (China) State Drug Administration. A randomized, double-blind, placebo-controlled, parallel group, multi-center clinical trial can be carried out. The presbyopia treatment market has huge commercial potential, particularly in China, where no pharmaceuticals have been approved for commercial use until now. The OT-802 phase III clinical trial authorization was obtained this time, which reflects the Group's research and development capabilities, and highlights that the current presbyopia treatment market is unsatisfied and has considerable potential.